Insurers Retreat from GLP-1 Coverage as FDA Advances Eli Lilly Strategy

Health insurers are scaling back coverage for popular GLP-1 weight-loss and diabetes medications, while the FDA's recent regulatory moves provide Eli Lilly with a significant competitive advantage in the market.